<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205799</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002184-97</org_study_id>
    <nct_id>NCT04205799</nct_id>
  </id_info>
  <brief_title>Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure</brief_title>
  <acronym>CABOCOL-01</acronym>
  <official_title>A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical&#xD;
      cancer (CC) after failure of platinum-based regimen treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of cabozantinib: proportion of patients with disease control rate</measure>
    <time_frame>3 months after cabozantinib treatment initiation.</time_frame>
    <description>Efficacy assessed by the proportion of patients with disease control rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of cabozantinib: proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE v 5.0)</measure>
    <time_frame>toxicities occurring up to 1 month after the end of treatment</time_frame>
    <description>Safety assessed by the proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE v 5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response (RECIST v1.1 criteria)</measure>
    <time_frame>At the end of cycle 3,6,9... (each cycle is 28 days) through study completion, an average of 1 year</time_frame>
    <description>Objective response rate defined as the percentage of patients who have achieved complete response or partial response with RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>At the end of cycle 3,6,9... (each cycle is 28 days) through study completion, an average of 1 follow-up year</time_frame>
    <description>Progression-free survival, defined as the time between initiation of cabozantinib treatment and progression (RECIST 1.1 criteria) or death of any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 1 follow-up year</time_frame>
    <description>Overall survival, defined as the time between initiation of cabozantinib treatment and death of whatever cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of cabozantinib</measure>
    <time_frame>every cycle of treatment (each cycle is 28 days) through study completion, an average of 1 follow-up year</time_frame>
    <description>Toxicities evaluated according to NCI CTCAE v5.0 criteria, in terms of kind, grade, time of onset, reversibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment Quality-of-life of patients assessed by EORTC QLQ-C30 /CX24 questionnaire</measure>
    <time_frame>At Day 15 of cycle 2 (each cycle is 28 days) and every 3 cycles of treatment ((every 12 weeks)) an average of 1 follow-up year</time_frame>
    <description>Scores of Quality-of-life according to French versions of the self-administered standardized validated questionnaire: EORTC QLQ-C30 with CX24</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Advanced/Metastatic Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>CABOZANTINIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.</description>
    <arm_group_label>CABOZANTINIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female 18 years of age or older&#xD;
&#xD;
          -  Histologically confirmed recurrent unresectable or metastatic cervix carcinoma with&#xD;
             squamous cell, adenocarcinoma or adenosquamous histology - - Patient may have received&#xD;
             at least one prior chemotherapy regimen of platinum-based chemotherapy for recurrence&#xD;
             or metastatic disease.&#xD;
&#xD;
          -  Cisplatin given in combination with radiation for a localized disease does not count&#xD;
             as a prior chemotherapy.&#xD;
&#xD;
          -  Prior treatment for advanced/metastatic disease with bevacizumab is allowed.&#xD;
&#xD;
          -  Prior treatments with immune checkpoint inhibitors are allowed. - ECOG performance&#xD;
             status 0-2 - Measurable disease per RECIST 1.1&#xD;
&#xD;
          -  The subject must have recovered to baseline or CTCAE v.5.0 (Common Terminology&#xD;
             Criteria for Adverse Events, version 5.0) ≤ Grade 1 from clinical toxicities related&#xD;
             to any prior treatments, i.e chemotherapy or pelvis radiation unless AE(s) are&#xD;
             clinically non-significant (for example alopecia)&#xD;
&#xD;
          -  Adequate organ and marrow function, defined as follows, based upon laboratory tests&#xD;
             performed within 7 days before inclusion:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000/mm3 (≥ 1.0 GI/L)&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm3 (≥ 100 GI/L)&#xD;
&#xD;
               -  Hemoglobin ≥ 10 g/dL (≥ 100 g/L) (red blood cell transfusion is allowed)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 fold the upper limit of normal (for subjects with Gilbert's&#xD;
                  disease, ≤ 3 mg/dL or ≤ 51.3 μmol/L) o Serum albumin ≥ 3.0 g/dL (≥ 30 g/L)&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 mL/min by the CKD-EPI method.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 3.0 x the&#xD;
                  upper limit of normal&#xD;
&#xD;
               -  Urine protein/creatinine ratio (UPCR) ≤ 1g/g (≤ 113.17 mg/mmol creatinine) or&#xD;
                  24-hour urine protein &lt; 1 g&#xD;
&#xD;
          -  Left-ventricular ejection fraction ≥ 50%&#xD;
&#xD;
          -  Subjects affiliated to an appropriate social security system&#xD;
&#xD;
          -  Female subjects of childbearing potential must not be pregnant at screening and during&#xD;
             treatment by Cabozantinib. Effective methods of contraception should be used&#xD;
             throughout the course of treatment and for at least 4 months after the end of&#xD;
             treatment. Sexually active fertile subjects and their partners must agree to use&#xD;
             medically accepted barrier methods of contraception (e.g., male or female condom)&#xD;
             during the study and 4 months after the last dose of study treatment, even if oral&#xD;
             contraceptives are also used.&#xD;
&#xD;
          -  Before patient registration, written informed consent must be given according to&#xD;
             ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             gastrointestinal bleeding and/or fistula / perforation including, but not limited to:&#xD;
             Active peptic ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis,&#xD;
             Crohn's disease), history of abdomino and/or pelvic fistula, gastrointestinal&#xD;
             perforation, or intra-abdominal abscess, gastro-intestinal obstruction&#xD;
&#xD;
          -  Patients with lesions on baseline pelvic MRI which may major the risk of abdominal&#xD;
             and/or pelvic fistula/perforation&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may affect absorption of&#xD;
             investigational product including, but not limited to: malabsorption syndrome, major&#xD;
             resection of the stomach or small bowel.&#xD;
&#xD;
          -  Previously identified allergy or hypersensitivity to components of the study treatment&#xD;
             formulations (Note: patients with rare hereditary problems of galactose intolerance,&#xD;
             the Lapp lactase deficiency or glucose-galactose malabsorption should not take&#xD;
             cabozantinib and are also excluded).&#xD;
&#xD;
          -  History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months: Cardiac angioplasty or stenting, myocardial infarction, unstable angina,&#xD;
             coronary artery bypass surgery, symptomatic peripheral vascular disease, class III or&#xD;
             IV congestive heart failure, as defined by the New York Heart Association (NYHA),&#xD;
             serious cardiac arrythmias.&#xD;
&#xD;
          -  Corrected QT interval (QTc) calculated by the Fridericia formula &gt; 500 msec within 28&#xD;
             days before inclusion (see Annex for Fridericia formula). Note: if initial QTcF is&#xD;
             found to be &gt; 500 msec, two additional ECGs separated by at least 3 minutes should be&#xD;
             performed. If the average of these three consecutive results for QTcF is ≤ 500 msec,&#xD;
             the subject meets eligibility in this regard.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure (SBP) of &gt; 150 mmHg or&#xD;
             diastolic blood pressure (DBP) of &gt; 100 mmHg despite an optimal treatment.&#xD;
&#xD;
          -  History of cerebrovascular accident including transient ischemic attack (TIA),&#xD;
             symptomatic pulmonary embolism or untreated deep venous thrombosis (DVT) within the&#xD;
             past 6 months. Note: Subjects with recent DVT or asymptomatic pulmonary embolism who&#xD;
             have been treated with therapeutic anti-coagulating agents for at least 4 weeks are&#xD;
             eligible.&#xD;
&#xD;
          -  Major surgery or trauma within 28 days prior to first dose of investigational product&#xD;
             and/or presence of any non-healing wound, fracture, or ulcer.&#xD;
&#xD;
          -  Evidence of active bleeding or pathologic conditions that carry high risk of bleeding&#xD;
             such as coagulopathy or tumor involving major vessels.&#xD;
&#xD;
          -  At least 6 weeks must have elapsed between the last dose of pelvis palliative&#xD;
             radiation and the first dose of cabozantinib or 2 weeks for other localization of&#xD;
             palliative radiation&#xD;
&#xD;
          -  Presence of brain metastases or epidural disease unless adequately treated with&#xD;
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months&#xD;
             before inclusion. Eligible subjects must be neurologically asymptomatic and without&#xD;
             corticosteroid treatment at the time of inclusion.&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A4 inhibitors or inducers.&#xD;
&#xD;
          -  Patients with second primary cancer, except adequately treated non-melanoma skin&#xD;
             cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 3&#xD;
             years&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Concurrent participation in any therapeutic clinical trial&#xD;
&#xD;
          -  Patient deprived of liberty or placed under the authority of a tutor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elodie COQUAN, MD</last_name>
    <phone>(33)231455050</phone>
    <email>COQUE@baclesse.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie ABADIE LACOURTOISIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie COQUAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar LAMBRET</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril Abdeddaim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier TREDAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique D'HONDT, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Sebastien FRENEL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut CURIE</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana BELLO-ROUFAI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emeline COLOMBA-BLAMEBLE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>advanced/metastatic</keyword>
  <keyword>Cabozantinib</keyword>
  <keyword>platinum treatment failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

